LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Photo by bermixstudio from unsplash

TO THE EDITOR: Waldenstrom macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with immunoglobulin M monoclonal gammopathy.[1][1] The majority of patients carry the L265P mutation in MYD88,[2][2] whereas 40% of… Click to show full abstract

TO THE EDITOR: Waldenstrom macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with immunoglobulin M monoclonal gammopathy.[1][1] The majority of patients carry the L265P mutation in MYD88,[2][2] whereas 40% of patients carry mutations in CXCR4.[3][3] Mutation status has an

Keywords: impact cxcr4; negative impact; macroglobulinemia; waldenstrom macroglobulinemia; bortezomib overcomes; overcomes negative

Journal Title: Blood
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.